Months after qualifying medical cannabis moved to Schedule III, cannabis businesses still lack detailed IRS guidance on how to allocate Section 280E relief across mixed medical and adult-use operations, and the last 2026 estimated payment for calendar-year C corporations is due December 15. The legal change is real. The implementation instructions remain incomplete.
Image: Pexels
What is Section 280E and why does it matter?
Section 280E denies deductions or credits for businesses trafficking in Schedule I or II controlled substances. That rule produced unusually high effective federal tax burdens across the cannabis industry while marijuana was treated uniformly as Schedule I.
The federal baseline changed in April 2026. DEA materials now distinguish FDA-approved marijuana products and medical marijuana products regulated under qualifying state licenses, which moved to Schedule III, from the remainder of marijuana, which remains the subject of the broader rescheduling proceeding. That split means 280E can no longer be analyzed as one cannabis-wide tax rule.
Public-company filings already reflect that distinction, but mixed operations still face practical questions about how to attribute shared expenses, inventory, facilities and personnel. For the broader framework and historical exposure, see 280E Is No Longer One Cannabis Tax Story.
Why are dual-license operators in the hardest spot?
The hard case is the dual-license operator. Missouri, for example, issues comprehensive licenses covering both medical and adult-use sales, and plants, staff and buildings can be shared across both. At retail the distinction may be visible through the purchaser and transaction. Upstream, allocating shared costs can be much less obvious.
That is why the missing guidance matters. Schedule III treatment may change the federal tax result for qualifying medical activity, but it does not by itself tell a mixed operator how every shared dollar should be allocated.
What should operators do before December 15?
Tax positions should be built around documentation and defensible allocation rather than the assumption that either total relief or zero relief must apply to the entire enterprise. Secondary reporting describes advisers modeling multiple scenarios—no relief, medical-only relief on a supportable split and the largest position they believe can be justified—while waiting for more specific federal guidance.
This is an area where operators should work with their own qualified tax advisers. The useful management question is whether the business has records detailed enough to support whichever position it ultimately takes.
How does this connect to DEA registration?
The tax and registration stories are two sides of the same implementation problem. DEA has begun issuing federal registrations to qualifying medical dispensaries, but registration, supply-chain compliance and tax treatment are distinct federal systems. Read DEA Issues First Federal Registrations to Medical Cannabis Dispensaries for the operating side of the transition.
Frequently Asked Questions
What is Section 280E?
It is a federal tax rule that denies deductions or credits for businesses trafficking in Schedule I or II controlled substances.
Does 280E still apply to every cannabis business in the same way?
No. The 2026 federal framework creates a distinction between qualifying medical activity moved to Schedule III and marijuana activity that remains in Schedule I, making business line and tax period important to the analysis.
Why does the December 15 deadline matter?
For calendar-year C corporations, December 15 is the fourth estimated federal income-tax installment date, so businesses may need to take a position before more detailed allocation guidance arrives.
What should mixed medical/adult-use operators focus on?
Documentation, defensible allocation methods and advice tailored to their own structure rather than assuming the same treatment applies to every dollar of the business.